Skip to main content

Genedata expanding its user network

| News

Genedata expanding its user network


The Japanese biopharmaceutical firm Ajinomoto is to use the Genedata solution to accelerate its drug development processes at its site in South Korea as well. The location in China is set to follow suit in due course. Other pharmaceutical firms are also increasingly turning to the IT solution developed in Basel.

Ajinomoto is to integrate Genedata Bioprocess at its research and development locations in Japan and South Korea. The Japanese biopharmaceutical firm is using the solution developed by the Basel-based IT company Genedata, which specializes in the life sciences sector, as a central data backbone to streamline cell culture media development and production operations, including in regulated environments, further details of which can be found in a press release issued by Genedata.

Ajinomoto has been using Genedata Bioprocess in Japan for around a year now. “The platform integrates with our existing laboratory instrumentation, allowing us to evaluate huge volumes of cell culture media development data at a level of complexity that was previously unimaginable”, comments Hiroyuki Mise, General Manager Biopharma Solutions Group, Amino Acids Department at Ajinomoto, in the press release. Use of the solution is now being expanded to the teams in South Korea to facilitate cross-site projects. There are also plans to include the company’s location in China in the future.

More customers acquired

“I am delighted to see that Ajinomoto is expanding the usage of Genedata Bioprocess across its Asian development and manufacturing sites, which is how we envision our platform to be used,” says Othmar Pfannes, CEO of Genedata, headquartered in Basel.

It was only in May that Debiopharm decided to use the Genedata Profiler. It allows the Lausanne-based pharmaceutical firm to quickly convert scientific findings into therapeutic products, thereby improving the success of clinical trials. In December, Genedata announced that Icosagen Cell Factory in Estonia would be using Genedata Biologics to digitize and automate its recombinant antibody discovery services. In October 2022, the French firm Sanofi also opted to use Genedata Biologics at additional research and development sites.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.